Podcasts about Kishan

Featuring in this episode are: Aditya Joshi (Team Sports Katta) https://x.com/aditya1387 Amol Karhadkar (Deputy Editor, The Hindu) https://x.com/karhacter इशान किशन गेल्या वर्षी BCCI च्या कॉंट्रॅक्टमध्ये नव्हता? यावर्षी असं काय बदललं? अभिषेक नायरचा पत्ता कट होणार हे भाकित स्पोर्ट्स कट्टाने आधीच वर्तवलं होतं, ते इंग्लंड दौ-याच्या आधी झालं. श्रेयस अय्यर आणि विराट कोहली यांच्यामध्ये तुझी नि माझी खुन्नस असं का झालं? १४ वर्षांचा वैभव आणि १७ वर्षांचा आयुष यांनी IPL मध्ये पदार्पणातच युवा पिढीची बेदरकार बॅटिंग दाखवली. मुंबई इंडियन्सने वानखेडेवर चेन्नईसमोर मोठा विजय मिळवत प्ले ऑफच्या दावेदारीमध्ये आपण आहोत हे दाखवून दिलंय. अशा अनेक ट्रेंडिंग टॉपिक्सवर वीकली कट्टामध्ये गप्पा मारत आहेत आदित्य जोशी आणि द हिंदूचे अमोल क-हाडकर Follow us on: YouTube: https://www.youtube.com/@SportsKattaMarathi Instagram: https://www.instagram.com/sportskattamarathi Facebook: https://www.facebook.com/SportsKattaMarathi Twitter: https://twitter.com/Sports_Katta Email : barachkaahi@gmail.com

Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in the MARCAP Consortium.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00034-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this episode of the show, Binksy, Baldy, Jamie and Stu look back at week 1 of IPL 2025 through a stock market lens. Who are we buying? Who are we selling? And what are we watching with our fingers poised ready to pounce in the coming weeks? We start on a positive note, highlighting a balanced RCB side unbeaten at the time of recording thanks to a bowling attack featuring the quality of Josh Hazlewood and a top order that's firing thanks to Phil Salt, Virat Kohli, Rajit Patidar and co. In the Buy section of the show there's also praise for Sai Sudharsan, MS Dhoni and wicketkeepers in general. We're watching the impact player performances and how that's impacting games and batting lineups. We're selling a star-studded Mumbai Indians batting lineup featuring Rohit Sharma, Suryakumar Yadav, Tilak Varma, Hardik Pandya and friends because we can't understand why they're continuing to struggle, and watching closely to see how much tinkering do with their teamsheet, tactics and batting lineup with the likes of Curran, Dhoni, Jadeja and Ashwin who could all slide up and down the middle order. To round out the show, there's chat about whether teams will score 300, how home ground advantage could play a role and if it is too early to be worried about Pat Cummins and his SRH bowling attack. We'll be back in your feed later in the week with more of a game review style show. If you're enjoying our content then please take the time to give us a like, follow, share or subscribe on all our channels (@toporderpod on Twitter & Facebook, and @thetoporderpodcast on Instagram & YouTube) and a (5-Star!) review at your favourite podcast provider, or tell a friend to download. It really helps others find the show and is the best thing you can do to support us. You can also find all our written content, including our Hall of Fame series, at our website. You can also dip back into our guest episodes - including conversations with Mike Hesson, Shane Bond and Mike Hussey, current players such as Matt Henry, Sophie Devine and Ish Sodhi, coaches Gary Stead, Jeetan Patel and Luke Wright, as well as Barry Richards, Frankie Mackay, Bharat Sundaresan and many more fascinating people from all across the cricketing world. And if you'd like to reach out to us with feedback, questions or guest suggestions, get in touch at thetoporderpodcast@gmail.com. Thanks for listening. 0:00 Intro 2:00 Buy - RCB top of the table thanks to Hazlewood, Salt, Patidar & co. 5:05 Buy - Wicketkeepers: MS Dhoni, Jurel, Kishan, Buttler, De Kock, Pooran 7:05 Buy - Sai Sudharsan & GT's batting lineup 9:00 Watch - Impact player performances 17:50 Sell - Mumbai Indians - Why are they struggling with the bat? 24:05 Sell - Umpire review of wides 26:20 Sell - Do seam bowlers need more craft? 33:20 Sell/Watch - CSK's batting order Ashwin/Jadeja/Curran/Dhoni 37:45 Watch - Will we see 300 scored this season? 41:55 Watch - Is SRH's bowling lineup a concern? 45:05 Watch - Variation across venues Learn more about your ad choices. Visit podcastchoices.com/adchoices

Two new questions, two fresh answers - let's dive in!  (0:40) Kishan has five properties in his portfolio, and with several remortgages due soon, he's weighing up his options on arrangement fees and asks Rob & Rob if it's better to pay upfront or roll the cost into the loan.  (4:52) Gareth's curious about property crashes and wants to know how they're defined, if there's a specific percentage drop that signals a crash, and what steps investors can take to protect their portfolios from the impact.  Enjoy the show?  Leave us a review on Apple Podcasts - it really helps others find us!  Sign up for our free weekly newsletter, Property Pulse  Send us your question by calling us on 013 808 00035 and leaving a message with your name and question (normal UK call rates apply) or click here to leave a recording via your computer instead.  Find out more about Property Hub Invest 

Sundeep Kishan enters the Permit Room and talks about why he chose the title People Star, his funny story with Rajinikanth, being a lucky charm, auditioning for Raj & DK, Lokesh Kanagaraj, Dhanush, Vijay Sethupathi, SWOT analysis of his career and much more.Chapters: 00:00 - People Star5:50 - Telling Rajinikanth not to smoke and not working in Coolie7:47 - 15 years in the industry9:11 - Heroine's and director's lucky charm14:21 - Cinema has influenced many aspects of his life15:51 - IPS dreams19:21 - Raj & DK don't like killing characters21:56 - How he convinced Raj & DK27:46 - Working with Lokesh Kanagaraj and Dhanush early on in their careers29:44 - SWOT analysis of his career35:03 - Insecurities as a lead actor39:39 - Being spiritual46:07 - How was his pandemic?47:24 - Taurus traits49:44 - When will he get married?53:13 - Crazy fan encounter58:53 - Preparation to becoming an actor1:06:38 - Being in touch with Venky Atluri and Shreya Dhanawarthy1:11:36 - Member questions1:15:31 - Working opposite Vijay Sethupathi, Dhanush, Manoj Bajpai and more1:25:36 - Member questions1:46:55 - Fitness routine1:52:17 - Why should we watch Mazaka?

Music

Joining Iain Dale on Cross Question this evening are Labour MP Chris Curtis, entrepreneur Emma Sinclair, former Tory MP Matt Warman and political strategist Kishan Devani.

Si alguien me hubiera dicho hace unos años que acabaría escribiendo un libro de consejos, le habría dado un puñetazo en la nariz por hacerme enojar. Quiero decir, a menos que el consejo sea cómo terminar muerto o en la cárcel, no estoy exactamente calificado. Soy Ozzy Osbourne, no la maldita Oprah Winfrey. Pero aquí estoy: “Dr. Ozzy”, como me llama la gente ahora. Y para ser totalmente honesto, me encanta esto. Nos encantan los libros y compartimos nuestro gusto por la lectura. Hablamos de cómics y libros, también publicamos noticias del mundo literario y lo que se nos ocurra sobre lo que amamos, los libros. Tienda: https://www.redbubble.com/people/bpmundial/shop?asc=u Apóyenos con una donación en: https://www.patreon.com/bpmundial https://ko-fi.com/bpmundial https://www.paypal.me/bpmundial https://streamlabs.com/bpmundial https://streamelements.com/bpmundial/tip https://facebook.com/becomesupporter/BibliotecaPublicaMundial/ Síganos en nuestras redes sociales: Instagram de Conan: https://www.instagram.com/conanthelibrarian83 Discord: https://discord.gg/S8dq65GmcN Instagram: https://www.instagram.com/bibliotecapublicamundial/ Facebook: https://www.facebook.com/BibliotecaPublicaMundial/ Youtube: https://www.youtube.com/c/BibliotecaPúblicaMundial Twitch: https://www.twitch.tv/bpmundial Twitter: https://twitter.com/bpmundial Tiktok: https://www.tiktok.com/@bpmundial Links: https://linktr.ee/bpmundial Escuchen nuestro Podcast en las plataformas: Apple Podcasts Google Podcasts Anchor: https://anchor.fm/bibliotecapublicamundial Breaker: https://www.breaker.audio/biblioteca-publica-mundial Pocket Casts: https://pca.st/j8njh92w RadioPublic: https://radiopublic.com/biblioteca-pblica-mundial-Gy9Kqx Spotify: https://open.spotify.com/show/4Eqj0XQ43vdHzp6B09fdrA También en esas plataformas denle click en suscribirse y compartan

Exciting insights

Biochemical recurrence of prostate cancer can be difficult to diagnose and treat. In this episode of BackTable Urology, where Dr. Aditya Bagrodia hosts Dr. Amar Kishan, a genitourinary radiation oncologist at UCLA, to discuss the complexities of biochemical recurrence and local failure after radiation therapy for prostate cancer. --- This podcast is supported by: Veracyte https://www.veracyte.com/decipher --- SYNPOSIS First, they evaluate alternatives to androgen deprivation therapy (ADT), the benefits and risks associated with ADT, and the role of genetic classifier tests. They also detail the goals of prostate-specific antigen (PSA) monitoring, PSA trends post-radiation, and advancements in PSMA PET scans. Then, the conversation highlights modern treatment options like targeted radiation, low dose rate brachytherapy, salvage radical prostatectomy, and focal therapy. Finally, the doctors emphasize personalized and multidisciplinary treatment plans as they hope to improve long-term outcomes for patients with prostate cancer. --- TIMESTAMPS 00:00 - Introduction 04:31 - PSA Levels Post-Radiation 13:21 - Local Recurrence and PSMA PET 21:29 - Explaining Radiation Effects to Patients 22:41 - Managing PSA Bounce 26:05 - Imaging and Biopsy Techniques 28:55 - Treatment Options for Local Recurrence 30:16 - Re-Irradiation and Focal Therapy 33:13 - Concluding Thoughts --- RESOURCES Veracyte https://www.veracyte.com/

JCO PO author Dr. Amar U. Kishan, Professor, Executive Vice Chair, and Chief of Genitourinary Oncology Service in the Department of Radiation Oncology at the University of California, Los Angeles, shares insights into his JCO PO article, “Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study.”  Host Dr. Rafeh Naqash and Dr. Kishan discuss the relationship between Decipher genomic classifier scores and prostate-specific membrane antigen (PSMA) PET/CT-based metastatic spread. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO articles. I'm your host, Dr. Rafeh Naqash, Assistant Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today we are joined by Dr. Amar Kishan, Executive Vice Chair of the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and UCLA Jonsson Comprehensive Cancer Center, and also the corresponding and senior author of the JCO Precision Oncology article entitled, “Transcriptomic Profiling of Primary Prostate Cancers and Non Localized Disease on Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study.” Dr. Kishan, welcome to our podcast and thank you for joining us today. Dr. Amar Kishan: Thank you so much for that kind introduction and the invitation to be here today. Dr. Rafeh Naqash: Well, it seems to me that there's a theme that people in the GU space, investigators in the GU space, are very interested in trying to understand risk predictors for prostate cancer. We had somebody, I believe from Huntsman Cancer Center a few months back on a previous podcast, where they were trying to do risk prediction modeling as well. Could you tell us why that's something that the GU community is very interested in? What's the background? Is it because there's no risk prediction approaches currently? And would this somehow influence management in the near future? Dr. Amar Kishan: Yeah, that's a great question. So, I think this goes back to the point that we're in the era of precision medicine now, and many cancers have these molecular stratification scores and all that. Prostate cancer has lagged a little bit behind in that regard, despite the fact that it's such a common cancer that affects so many people across the country and across the world. So, we do have risk stratification schemes for prostate cancer. These are based off clinical and pathologic variables, like the level of PSA, the size of the tumor on digital rectal examination, now, we're incorporating MRI imaging as well, and then what the cancer looks like under the microscope, the Gleason score. And now there have been revisions to the Gleason score, but it's really kind of the architecture, what the biopsy looks like. And this was kind of developed many, many years ago by Donald Gleason, a pathologist at the VA. What we're not necessarily taking into account routinely is kind of the biology of the cancer per se. You know, what are the molecular drivers? How could that influence ultimate outcome? And that's very important because we have these risk groups, low risk, very low risk, favorable intermediate risk, unfavorable intermediate risk, high risk, very high risk. But within each of those groups, based on the clinical kind of pathological characteristics, there's a huge heterogeneity in outpatients too, and our treatments are effective, but they can be morbid. Putting someone on hormone therapy for an extended period of time has a lot of side effects. Dose escalating radiotherapy or doing surgery and then radiation afterwards, these are big things that have a big impact on the patient, and I think we really need better risk stratification tools to understand who needs intensification and who we can de-escalate treatment for. Dr. Rafeh Naqash: I think those are absolutely valid points, perhaps not just for prostate cancer, more so for all cancers that we currently treat, especially in the current day and age, where we have a tendency to add more and more therapies, combination therapies for patients, and as you mentioned, risk stratification to help identify high risk versus low risk, where you can de intensify treatment, is of high value from a patient standpoint as well as from a financial toxicity standpoint. So then, going to this next part of the approach that you used, and from what I understand in this paper, you had the radiological aspect, which is the PSMA PET, which we'll talk about. Then you had the genomic aspect, where you did some genomic risk-based stratification. Then you had the transcriptomic score based on the Decipher score. So, could you go into some of the details, first, for the PSMA PET, when is it used? What is the utilization? What is it based on, the science behind the PSMA PET? And then we can talk about some of the other genomic transcriptomic predictors that you use in this study. Dr. Amar Kishan: Sure. Absolutely. So, a PSMA PET is an advanced molecular imaging tool. PSMA stands for prostate specific membrane antigen. It's a membrane protein that is expressed on the surface of prostate cancer cells. It is expressed elsewhere in the body as well. The utilization of this for imaging has been a revolution in the staging of prostate cancer, both upfront and in the recurrent setting. We basically had fairly recent approval for PSMA PET being used more routinely in upfront staging and recurrent staging in 2022. Essentially, what this is it gives us an ability to detect whether prostate cancer has spread at a time of diagnosis or try to localize the recurrence. Now, no imaging test is perfect, of course, and a PET has a resolution of about 3 mm. There are questions about the sensitivity of the PET. You get it on a patient with high-risk disease, the PET is negative; you do surgery, there are positive lymph nodes. That can happen, but it's far superior to the tools that we have had before. For instance, beforehand, all we would have is a contrast enhanced CT, bone scan, and MRI. And the sensitivity of those is far below that of a PSMA PET. And that has actually been shown in a randomized trial called the ProPSMA trial out of Australia, where they compared conventional upfront imaging versus PSMA upfront imaging with a crossover design, and there was better detection of disease with the PSMA PET. So that's been a revolution in how we stage prostate cancer. But I'm sure many of your listeners and others are aware of the concerns. When you get a new test and you're detecting disease that's extra prostatic, for instance, are you seeing truly significant new disease that we do need to change our management for, or are we just seeing stuff that wasn't there before that actually wouldn't impact anything? And what I mean by that is, let's say you're seeing things that would never have made a difference to the patient, but now you're saying they have metastatic disease. You're changing their entire treatment paradigm, all kinds of things like that. There's implications to this that hasn't been fully fleshed out. But very recently, like we're talking in July of 2024, essentially, there was a Lancet Oncology paper that looked at the long-term prognosis of patients who had extra prostatic disease on PSMA PET, judged by something called a PROMISE score, kind of gives a quantification on the volume of disease, the brightness of disease, and they correlated that with long term outcomes. And that was really the first time that we have long term follow up data that this extra prostatic disease on PSMA PET actually is prognostically important. So, we're getting there. I mean, now that it's approved and, in some sense, the cat is out of the bag, patients are coming in asking for a PSMA PET, etc. I'm sure everyone has experienced that, but I think we now do have good evidence that it actually is prognostically important as well. Dr. Rafeh Naqash: Thank you for that explanation. And again, to put this into context for things that I've seen and that might also help the listeners in other tumors, so, for example, melanoma surveillance tends to be or while on treatment, patients tend to have more PET scans than what you see, maybe in individuals with lung cancer, where you get a baseline PET and then you have follow up CT scan based imaging is that something that you guys have shifted from in the prostate cancer space with the approval for PSMA PET, where follow up imaging, whether patient is on treatment or surveillance imaging, is PSMA PET based? Dr. Amar Kishan: Yeah, that's a good question. I think there's actually less robust data to support it as a means of treatment response. But in terms of evaluating a recurrence, then, yes, that has become kind of a standard tool. It's very complicated because all of the metrics that we have for, say, a treatment failing are based on conventionally detected metastases or something that shows up on a CT or bone scan. So, again, that question arises if someone is on systemic therapy and then you see something on a PSMA PET, are you going to abandon the therapy that you're on? It technically would be earlier than you would otherwise have done that, or what are you going to do? So, that hasn't been fully fleshed out, but it is used in that circumstance. So, I'd say less for treatment monitoring and more for evaluation of suspected recurrence. Dr. Rafeh Naqash: Understood. And I'm guessing, as a futuristic approach, somebody out there may perhaps do a trial using PSMA PET based imaging to decide whether treatment change needs to be made or does not need to be made. Dr. Amar Kishan: Yeah. It is being incorporated into trials as we speak, I think. Dr. Rafeh Naqash: Now, going to the second part of this paper is the Decipher score. Could you explain what the score is, what its components are, how it's calculated? Is it DNA, is it RNA, is it both combined? Is it tissue based; is it blood based? Dr. Amar Kishan: Yeah. So, the Decipher is also an approved test now, was approved in 2018. What it is, essentially, and how it's derived is based on the idea originally that patients might have a recurrence after surgery for prostate cancer. And it's just a PSA recurrence. It's this way. It's literally what we call a biochemical recurrence. That patient might not have any problems, whereas other patients with a recurrence might go on to develop metastatic disease. And we didn't have a good way of determining which patient is which. Get back to that prognostic problem that we have. So, some investigators, they looked at men that had radical prostatectomy from 1987 to 2001 at the Mayo Clinic that had archived tissue. They looked at FFPE, or basically paraffin embedded tissue. They extracted the RNA and then did a microarray analysis and looked at transcriptomic signatures and wanted to see, could this discern the patients who had mets, who had clinically significant recurrences from those that didn't? And out of that exercise came the Decipher Genomic Classifier, which basically is based on 22 genes. These are involved with cell proliferation, etc., but it's an RNA-based, tissue-based assay. So, if you wanted to order a Decipher on somebody, you would need to use a biopsy or prostatectomy specimen to do so. Essentially, that the samples, they would take the highest grade, highest Gleason grade specimen, send it to their lab. Their main lab is in California. The company is called Veracyte. And then they will do this RNA express analysis with a microarray and then return a score. The score is 0 to 1. Basically, 0 is the lowest, one is the highest, and it is a way of prognosticating the risk of metastasis. Originally, when you get a Decipher report, it actually will tell you the 5 and 10-year risks of distant metastasis, and we'll quantify that. Dr. Rafeh Naqash: And you said this is approved or has been approved in 2018. So, is this insurance reimbursable at this point? Dr. Amar Kishan: Most insurances do, not all, and the criteria for getting it can vary, so we can talk about it, but it was initially developed in this post-op setting. On the basis of a significant amount of validation studies, it has been moved to being used in the upfront setting as well. So, if you look at some of the ongoing NRG trials, for instance, they are stratifying patients based off the upfront Decipher score. And this is based off of validation studies that have been conducted looking at past RTOG trials and other trials. That said, sometimes it is not approved by commercial insurances in the upfront setting, because that wasn't where it was initially validated and derived. But honestly, here in 2024, that's very uncommon. It's much more common that it's approved. Dr. Rafeh Naqash: Understood. And in your practice, or the medical oncologist practice at your institution or other institutions, is this something that is commonly used for some sort of treatment decision making that you've seen? Dr. Amar Kishan: Yeah. So, as a radiation oncologist, I do think it's a useful test, because my approach is, if we're talking about adding hormone therapy, for instance, which is oftentimes dominating the conversation, we know that it offers a relative benefit to a lot of patients. We've published on this; others have published on it. Let's say it reduces the chance of metastasis by about 40%. 10-year risk of metastasis has a ratio of 0.6. So, 40% reduction. But if your risk of metastasis is 2%, that benefit is not that much in absolute terms. And we don't historically have a great way of saying, what is your absolute risk of metastasis? And I think Decipher is one tool that does tell us that - it literally gives it on the report. Now, is that a holy grail? Is it 100% accurate? Nothing is 100% accurate. But it does give us some quantification. Then I can go back to the patient and say, yes, you will get a benefit from adding hormone therapy, but you're talking about going from 2% to 1%, and so they can decide if that's worth it to them. Conversely, it could be a situation where they really don't want hormone therapy, but it comes back that their risk of metastasis is 20%, and then there's actually a big absolute benefit. So that's how I use it as a radiation oncologist, and we would use it upfront. Now surgeons, and if I was consulting on a post operative patient, maybe it plays more of a role. And do we need to do post operative radiotherapy on this patient, or do we need to add hormone therapy in the postoperative situation? From the medical oncology perspective, there are emerging data that may be useful in the choice of systemic therapy for metastatic disease, but that is a little bit earlier in the investigational stage, I would say. So, when I'm working with medical oncologists, it's often still in this localized setting, and typically, do we add hormone therapy or not, and that type of thing. Dr. Rafeh Naqash: Understood. And from a reporting standpoint, so the Decipher score, I'm guessing it's some sort of a report that comes back to the ordering physician and you basically see the score, it gives you a potential recurrence free survival percentage or a metastasis percentage of what is your risk for having metastasis in the next five years - is that how they generally do it? Because I've personally never seen one, so I'm just curious. Dr. Amar Kishan: Yeah, essentially, it comes back with a score, a numerical score, again, from 0 to 1, and it will basically give you the five-year risk of distant metastasis. The ten-year risk of distant metastasis. You can request an extended report that provides additional, not as well supported signatures that are out there, like ADT response signature, etc. But those maybe may have been published, but are not clinically validated as much, but the actual Decipher report, which goes to patients too, just has this kind of 5,10-year risk of distant metastasis. They have some estimations on prostate cancer specific mortality as well. Dr. Rafeh Naqash: Sure. Now, the third part of this project, and correct me if I'm wrong, the grid database of the 265 genomic signature score. From what I understood, this is a different component than the Decipher score. Is that a fair statement? Dr. Amar Kishan: Yeah. No, that's exactly correct. And that was an exploratory part of this analysis, to be honest. Basically, I think our main focus in the paper was those advances that we've talked about PSMA and Decipher, those happened concurrently. People started developing PSMA PET, people started developing Decipher. And so, what we wanted to understand was, if you have a patient that has extra prosthetic disease on PSMA PET, are those biologically more aggressive cancers, is their Decipher score going to be higher? What can we learn about the biology of this? And we were the first, to my knowledge, where we actually had a large data set of patients that actually received PSMA PETs and Decipher. And that's kind of the gist of the paper. We have patients in the upfront setting, patients in the post radical prostatectomy setting, and we're essentially showing that there is this correlation. In the upfront setting, the odds of extra prosthetic disease are higher for higher Decipher scores, which is kind of maybe validating that this biology is capturing something that's akin to this ability to spread. And in the post-op setting, because we have time to failure, technically, we can calculate a hazard ratio rather than odds ratio. So, we have a hazard ratio that's significantly associated with an increased risk of spread for patients with higher Decipher. The grid portion, which is the genomic resource information database, was more of an exploratory part where I mentioned the Decipher score is based off this microarray, they're looking at 1.4 million transcripts. Only 22 are part of the Decipher, but you can request the rest of the signature data as well. And so, we wanted to look at other pathways, other signatures that have been published, like looking at DNA repair, neuroendocrine pathway, just to see if we could see any correlations there that's not necessarily as clinically actionable. These are more exploratory. But again, we were trying to just look at whether patients who had non localized disease on their PSMA PET, whether their primary had more aggressive biology. We did see that. So that's kind of loosely speaking things like PTEN loss, androgen receptor, DNA repair, metabolism, neuroendocrine signaling, which are thought to be portenders of aggressive disease. Those pathways were upregulated at the RNA level in patients who had non-localized disease. And that's kind of the take home from that. But I wouldn't say any of that is clinically actionable at this point. It's more kind of defining biology. Dr. Rafeh Naqash: Some of the interesting correlations that you make here, at least in the figures that we see, you're looking at different local occurrences, nodal metastases, M1A and M1B disease. And one thing that I'm a little curious about is the Decipher score seems to be lower in pelvic nodal metastasis, that is, PSMA PET positive versus local recurrence, which has a slightly higher Decipher score. Is that just because of a sample size difference, or is there a biologically different explanation for that? Dr. Amar Kishan: Yeah, that's a good point. I would assume that's probably because of a sample size in this case, and it's a little bit complicated. It wasn't statistically different. And it was 0.76 on average for patients with local recurrence and 0.7 for patients with a pelvic nodal metastasis. Well, what I think is interesting is we can maybe think that in this post-op setting the time to failure could have been long in some of these cases. So, it is conceivable that an isolated nodal recurrence 10 years after the surgery, for instance, is not as aggressive a cancer as a local recurrence in a short time after the surgery. And that's not taken into account when you're just looking at median scores like we are in this fox and whiskers plot. But overall, I think what it's suggesting is that there are patients who have more indolent disease. That's actually pretty widespread there. There are pretty indolent cases that have these nodal metastases. So just because you have a nodal metastasis doesn't mean it's an incredibly aggressive cancer, biologically. Dr. Rafeh Naqash: Now, the exploratory component, as you mentioned, is the grid part where you do look at TP53, which is a cell cycle gene, and higher TP53 associated with worse recurrences, from what I understand. Do you see that just from a cell cycle standpoint? Because from what I, again, see in the paper, there's a couple of other cell cycle related signatures that you're using. Is that just a surrogate for potential Gleason score? Have you guys done any correlations where higher Gleason score is associated with maybe higher cell cycle checkpoint, pathway related alterations and replication stress and DNA damage and perhaps more aggressive cancers? Dr. Amar Kishan: Yeah, that's a great question. We haven't done that in this paper, but it has been published before that there is this correlation loosely between grade and some of these parameters - so repair, metabolism, androgen receptor signaling. However, it's a very great point that you bring up, which is that it's pretty heterogeneous and that's why we need something like this as opposed to Gleason score. So, you can have Gleason 10 cancer. I mean, that would be pretty uncommon. But within the Gleason 9, at least, which we have published on and looked at, there's a heterogeneity. There are some that are biologically not that aggressive. And the converse Gleason 7, you can have some that are actually biologically aggressive. That's why it may be useful to move away from just the pathological architecture and get a little bit more into some of these pathways. Dr. Rafeh Naqash: What's the next step here? I know this perhaps isn't ready for primetime. How would you try to emphasize the message in a way that makes it interesting and clinically applicable for your colleagues in the GU community? Dr. Amar Kishan: Yeah. I think for me, what I would try to emphasize here and what I think is the main takeaway is this is kind of a validation that having extra prostatic disease on PSMA PET is likely suggestive of a more aggressive disease biology. And I think what this stresses to me is the importance of getting a PSMA PET, particularly in patients with high-risk prostate cancer. This isn't always happening. And I think if we see things on a PSMA PET, we really need to consider systemic therapy intensification. And what do I mean by that as a practical point? You have a high-risk prostate cancer patient. You get a PSMA PET, you see an isolated pelvic lymph node. If we believe the results of the study, that's a more aggressive biology likely. Whether we have the Decipher or whether we have genomic signatures, which we may or may not have, maybe that patient should get treated with something like an androgen receptor signaling inhibitor in addition to ADT, more akin to a clinically node positive case. So, intensify the systemic therapy, more aggressive disease. That's how I would incorporate it practically into my practice, that really what we're seeing on the PSMA PET is real. It's a reflection of biology that's aggressive. It's not just some Will Rogers effect where you're upstaging stuff needlessly. I think this is telling us some true biology. So that's kind of what my takeaway would be. I think future areas of investigation would be, honestly, to try to have a better idea of what's going on in these metastases. So, if you could design a study potentially, where your biopsy some of these and actually do sequencing and understand a little bit more of that. And so, we're looking into stuff like that. But my takeaway for like the everyday clinician would be to try to get a PSMA PET, if you can, and to intensify therapy on the basis of that, or at least consider it, discuss it in a multidisciplinary setting. Dr. Rafeh Naqash: And I'm guessing somebody out there, perhaps even you, are thinking or planning on doing a ctDNA MRD based correlation here, since that's up and coming in this space. Dr. Amar Kishan: That is up and coming, I think one of the challenges in prostate cancer is the amount of ctDNA can be low. But yes, you're right, that's certainly things that a lot of us are looking at, too. Dr. Rafeh Naqash: Excellent. Well, thank you for the science discussion, Dr. Kishan, could you tell us a little bit about yourself, your career trajectory, where you started, what you're doing, and perhaps some advice for early career junior investigators, trainees, things that might have worked for you, that could also work for them as they are progressing in their careers. Dr. Amar Kishan: Sure. So, yeah, I'm a radiation oncologist at UCLA. I run the prostate cancer radiation program. Clinically. I'm also heavily involved in our research enterprise, so I kind of oversee the clinical and translational research aspect. That's what I do currently. So, I did my residency in radiation oncology at UCLA. Just on a personal note, my wife is from LA, her parents live in LA. We really wanted to stay in LA, so I was fortunate to be able to join the faculty here. I always liked GU oncology, so that was kind of a natural thing for me to kind of go into this position here and try to build the GU program. I've been very fortunate to have great collaborators. My message to students and trainees is to try to reach outside your department for mentorship as well. It's important to have people inside your department who can mentor you. But as a radiation oncologist, I work so closely with urology, so closely with medical oncology that I'm very fortunate to have individuals in those departments who have a vested interest in me and my success as well. I like working with them. It's important to be a team player. If they need help, you help them. If you need help, you ask for help from them. So, I think that's the single biggest thing that I would say to any trainee is don't be intimidated. Please reach outside of your department. Lots of people are willing to help and provide mentorship, and it's helpful to have that perspective. We are in a very multidisciplinary environment and era of practicing medicine. Dr. Rafeh Naqash: Well, thank you again for those personal insights and especially for submitting your work to JCO PO. And we hope to see more of this work perhaps in the subsequent sessions for JCO PO, and maybe we'll bring you back again. And at that point, the Decipher and the PSMA PET scan will have more data, more implementation in the clinically relevant real-world setting. Dr. Amar Kishan: Thank you very much. And if I could just give one quick shout out. The first author of this work, which I presented, was Dr. John Nikitas, who is a trainee that works with me here at UCLA a PGY5 resident. So, I do want to give credit to him as well. Dr. Rafeh Naqash: And John, if you're listening to this hopefully, it's always great to get a shout out from your mentor. Thank you both again for putting in the work and effort to submit this manuscript. Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Disclosures  Dr. Kishan Honoraria Company: Varian Medical Systems, Boston Scientific,  Janssen Oncology  Consulting or Advisory Role Company: Janssen, Boston Scientific, Lantheus  Research Funding Company: Janssen , Point Biopharma

The baby boys are back with your weekly dose of Survivor action! Hosts @BriceIzyah, @WendellHolland, and @JackAtkins21 dive into Episode 4, where Rome's Steal-a-Vote flips the game, leading to Kishan's blindside at Tribal Council. With alliances crumbling and Genevieve making bold moves, the tension is high. Plus, a fierce immunity challenge shakes things up, and a brand-new Amulet Idol advantage promises even more chaos. Don't miss the strategy, twists, and surprises in this can't-miss episode!

David Bloomberg and Jessica Lewis welcome special guest Liz Wilcox to discuss what happened to ___ this week! It's good timing because in Survivor 46, Liz put a lot of work into molding what others thought of her, but this went wrong for ___ in a number of ways. The episode made it seem like Genevieve decided to turn on him because he used her name as a decoy. His interviews shed a different light, but opened up an expanded view into the way he was playing. We saw Rome as the chaotic player, but was it actually ___? At RHAP, we know Survivor, and we know Why ___ Lost.

David Bloomberg and Jessica Lewis welcome special guest Liz Wilcox to discuss what happened to ___ this week! It's good timing because in Survivor 46, Liz put a lot of work into molding what others thought of her, but this went wrong for ___ in a number of ways. The episode made it seem like Genevieve decided to turn on him because he used her name as a decoy. His interviews shed a different light, but opened up an expanded view into the way he was playing. We saw Rome as the chaotic player, but was it actually ___? At RHAP, we know Survivor, and we know Why ___ Lost.

The baby boys are back with your weekly dose of Survivor action! Hosts @BriceIzyah, @WendellHolland, and @JackAtkins21 dive into Episode 4, where Rome's Steal-a-Vote flips the game, leading to Kishan's blindside at Tribal Council. With alliances crumbling and Genevieve making bold moves, the tension is high. Plus, a fierce immunity challenge shakes things up, and a brand-new Amulet Idol advantage promises even more chaos. Don't miss the strategy, twists, and surprises in this can't-miss episode!

The baby boys are back with your weekly dose of Survivor action! Hosts @BriceIzyah, @WendellHolland, and @JackAtkins21 dive into Episode 4, where Rome's Steal-a-Vote flips the game, leading to Kishan's blindside at Tribal Council. With alliances crumbling and Genevieve making bold moves, the tension is high. Plus, a fierce immunity challenge shakes things up, and a brand-new Amulet Idol advantage promises even more chaos. Don't miss the strategy, twists, and surprises in this can't-miss episode!

Purple Pants Podcast | Alliance Cracks and Amulet Attacks The baby boys are back with your weekly dose of Survivor action! Hosts @BriceIzyah, @WendellHolland, and @JackAtkins21 dive into Episode 4, where Rome's Steal-a-Vote flips the game, leading to Kishan's blindside at Tribal Council. With alliances crumbling and Genevieve making bold moves, the tension is high. Plus, a fierce immunity challenge shakes things up, and a brand-new Amulet Idol advantage promises even more chaos. Don't miss the strategy, twists, and surprises in this can't-miss episode! You can also watch along on Brice Izyah's YouTube channel to watch us break it all down https://youtube.com/channel/UCFlglGPPamVHaNAb0tL_s7g BWPTour 47 Tickets: https://linktr.ee/briceandwenpresent LISTEN: Subscribe to the Purple Pants podcast feed  WATCH: Watch and subscribe to the podcast on YouTube SUPPORT: Become a RHAP Patron for bonus content, access to Facebook and Discord groups plus more great perks! Previously on the Purple Pants Podcast Feed: Purple Pants Podcast Archives Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Winner's Edit Podcast, Nick and Dan break down Genevieve's meteoric rise as she pulls off a killer move with Rome, taking Kishan down a notch in one of the season's biggest shockers yet! They discuss how so-called "invisible" characters can suddenly emerge from the shadows to shape the game—and how this season is becoming a masterclass in chaos. From the unexpected power plays to the bold confidence radiating from key players, Nick and Dan analyze how these dynamics could influence the season's outcome. Plus, here is a thought-provoking discussion: are those who claim to hate Edgic secretly drawn to it? Tune in as we dive into all the twists, turns, and complex characters making Survivor 47 one for the books!

You can click here to send us a text (We won't be able to see your phone number). If you're sending a topic to discuss on the show, please include a name to acknowledge you (first name, screen name, fake name, etc.)In this episode, the Purple Rock Podcast discusses:John's weather updateDid Genevieve make the right decision or was it a death row pardon two minutes too late?All discussions lead to Rome.The Sol of it all.Where it went wrong for Kishan.The new Amulet.Sue's got red on her.Maybe Sue is just a big fan of 45.Trouble in paradise for Sam and Sierra.The hip-hoppiest season of Survivor yet.Top 3 opening verses in hip-hop history.Spotify AI chapter breaks

Rome ... omg ... A new strategist emergesSue is how old? No, really ... how old? Where did Kishan go wrong? The new amulet

When in Rome Did Teeny and Kishan make the right decision? Should Aysha have turned on Sol? Poor Andy ... Kyle V Sue 

Today, Rob and Mike discuss two more players on the Lavo tribe, Kishan Patel and Rome Cooney.

Today, Rob and Mike discuss two more players on the Lavo tribe, Kishan Patel and Rome Cooney.

Kishan is on vacation and Nina is in charge! This episode is a compilation of 3 stories so silly, that they should be a crime! Don't wait! Dive on in and see what this episode is all about!

Welcome back to Season 16 of White Collars, Red Hands! This week we once again combine Kishan's love of baseball with disdain for financial crime into an episode as we talk about the background and friendship that formed between Shohei Ohtani and Ippei Mizuhara. Then we discuss how the friendship fell into ruin through a years-long heist.

For the past 10 years, Kishan's weight gain was literally weighing him down. He wanted to feel comfortable in his own skin. He didn't want to hold his breath while taking photos. And he wanted to wear a t-shirt that fit him perfectly. Despite his efforts, Kishan couldn't see the changes he desired. He trained twice a day Worked with a personal trainer Tried various diets and workout regimes But just couldn't nail the physique he desired! Disheartened but not defeated, Kishan refused to give up on his goals. That's when he discovered RNT. Kishan embarked on a transformative journey that changed his life forever. When he joined RNT he had one mission: Reach his potential in aesthetics and fitness. He wanted to see changes he hadn't seen before.”   And that's exactly what Kishan achieved. He surpassed his own expectations and revealed a newer, stronger version of himself, 20.5kg later. Today, Kishan radiates confidence and joy. He's thriving both physically and aesthetically, and I can't wait for you to hear his story. To see pictures, check out the case study linked in the show notes. And if you'd like to get results like Kishan, take the first step by booking a 1-1 call with my team on www.rntfitness.com/start.    Book A Call To Start Your Journey! Thanks so much for listening! If you like this episode, please subscribe to “RNT Fitness Radio” and rate and review wherever you get your podcasts:  Apple Podcasts  Stitcher iHeart Radio Spotify  I'm still loving our partnership with one of the world's leading premium supplement brands, Optimum Nutrition, they continue to support our RNT members, and listeners of this podcast, on their journey of health, fitness and total transformation. With the world's #1 best-selling protein powder in their range, and a growing plant-based range, you can use the code RNT20 to get 20% off in their US and UK stores. My personal favourite are their plant-based protein bars. I've literally done a 180 on protein bars since discovering these, and these were a game changer during my recent long stints in Bali and the US! You may be wondering if you're ready for a similar transformation. So I put together a quick 5 min free quiz for you to see if you have the three transformation keys required: commitment, consistency and coachability. In 40 yes/no questions, you'll know exactly what's holding you back from the results you see at RNT, with clear action steps on what to do next. Simply head to www.rntfitness.co.uk/transform to try the quiz. Resources: Are You Ready To Transform Scorecard Our Book: Transform Your Body, Transform Your Life   Follow RNT Fitness: Website Facebook Instagram YouTube  Email Follow Akash: Facebook Instagram LinkedIn

Nikesh Rughani & Megha Sinha look ahead to the final India v England test & predict how the XI's will line up. They also discuss the Iyer & Kishan contract situation & the WPL.Follow us On: Cricket8: https://cricket8.com/ -- Jarrod Kimber: Website: https://www.goodareas.coYoutube: https://www.youtube.com/@JarrodKimberYTYoutube: https://www.youtube.com/@GoodAreasLiveX: https://x.com/ajarrodkimber-- Rob Barron X: https://x.com/MonsieurJudge-- Megha Sinha Youtube: https://youtube.com/@meghasinha7126?si=VRisxCMpkQbsdZH2Facebook: https://www.facebook.com/share/45YXPLKiGbwvo2Si/?mibextid=LQQJ4dX: https://x.com/MeghaSinha006-- Machel St Patrick Hewitt Facebook: https://www.facebook.com/share/MC21uXUgCRyhrBsL/

Is Singapore's population losing its grip on mother tongue languages as we become more proficient in English? Two surveys by the Institute of Policy Studies on race, religion and language, found that while proficiency in English has risen, all ethnic groups have become less proficient in mother tongue languages. The eighth episode of the IPS On Diversity Podcast dive into the intricate mix of language, identity, and culture of Singapore. Liang Kaixin hosts the discussion with Dr Teo Kay Key, IPS Research Fellow, and Kishan Singh, a science educator who embarked on formally learning his mother tongue, Hindi, in his mid-20s. Dr Teo sheds light on the paradox of English proficiency in Singapore, where the mastery of the English language, while opening global doors, seems to have diluted proficiency in official mother tongues such as Mandarin, Malay, and Tamil. This decline in linguistic diversity sparks a deeper conversation about the loss of cultural identity and the implications for Singaporeans navigating their multilingual heritage. Kishan shares his personal journey, highlighting the challenges faced by non-Tamil Indian Singaporeans in connecting with their cultural roots through language. His experience underlines the broader societal and educational dynamics that influence language learning and retention among Singapore's minorities. In closing, the discussion touches on possible policy recommendations to Singapore's approach to language education. Dr Teo and Kishan propose innovative approaches to language learning that prioritise interest, relevance, and the removal of the stigma and shame associated with speaking mother tongues and dialects. Find out more about adulting and housing in Singapore: CNA (21 August 2022): Bad at Mother Tongue? What some parents are doing to help young ones be more fluent Straits Times (31 October 2023): Becoming proficient in English has come at a cost for many Singaporeans About our guests: Teo Kay Key, Research Fellow, Institute of Policy Studies Dr Teo Kay Key is Research Fellow at IPS Social Lab at the Institute of Policy Studies. She has a PhD in Political Science from the National University of Singapore. Her research interests are in political and social attitudes, public opinion, voting behaviour, and Singapore society. She is interested in examining these topics using a mix of quantitative and qualitative methods. Her current projects examine a myriad of issues in Singapore, including attitudes towards the family, social norms and values, and national identity. Prior to joining IPS, she worked in the civil service for nearly three years doing strategic planning, training, and policy work. She also has a Masters in Political Behaviour from the University of Essex in the United Kingdom and a Bachelors in Social Science from the Singapore Management University Kishan Singh, Adult learner of Hindi language, Science Educator Kishan Singh is a science educator with over 10 years of teaching experience, both in local and international schools. He also completed a secondment at the Ministry of Education concentrating on policy work around international students in our local schools. Since his MA in Science Education, he has an interest in how different groups perceive science, and how informal education, through social media and podcasts, has the potential to engage and involve wider audiences. He also does a podcast with his best friend called T42 available on Spotify and Apple Podcasts. More from On Diversity Season 4 Episode 7: Girl Math and the Gender Gap in STEM Field with Sieren Lim, Associate Professor at NTU, and Ainul Md Razib, Founder AinLovesCode Season 4 Episode 6: Youth and Climate Anxiety with Melissa Low, Research Fellow at NUS and Darren Quek, Principal of Forest School Singapore Season 4 Episode 5: Youth and Caregiving with Tan Poh Lin, Senior Research Fellow at IPS and Jason Leow Season 4 Episode 4: Home Alone and Adulting with Chew Han Ei, Adjunct Senior Research Fellow at IPS and Klinsen Soh Season 4 Episode 3: Hustle Culture and Quiet Quitting with Laurel Teo, Senior Research Fellow at IPS and He Ruiming, Founder of The Woke Salaryman Season 4 Episode 2: Destigmatising HIV and AIDS with Rayner Tan, Assistant Professor of NUS and Terry Lim, Associate Director of Action for AIDS Season 4 Episode 1: The Dual Challenges of Poverty and Single Motherhood with Carrie Tan, MP, Founder of Daughters of Tomorrow and Elizabeth Quek, Programme Manager at AWARE Season 3 Episode 9: Being Biracial in Singapore with Shane Pereira, Research Associate at IPS and Dave Parkash, Co-Founder at Fook Kin Restaurant See omnystudio.com/listener for privacy information.

Hey everyone, we said we wouldn't be back until the new year, and we are also filthy liars! We're dropping a relaxed feel, unscripted bonus episode talking about holiday hijinks, Christmas cons, and Kishan gives a gift by telling you about one of his favorite people in history, the delightfully stupid and lucky Lord Timothy Dexter. Happy Holidays!

Discussed in this episode: Joel may have bronchitis, Kishan is attacked by a gay in public, some smartass clearly thought it'd be fun to gamify digital literacy for seniors, a Brisbanite hits on Joel and it goes badly for all involved, the magical world of oud, and for some reason: Joakim Gomez.

This episode explores the developing trend of converting hotels into new multifamily properties with Ryan Bodine and Kishan Gohel of NewGen Advisory.The Crexi Podcast explores various aspects of the commercial real estate industry in conversation with some of the top CRE professionals in the space. In each episode, we feature different guests to tap into their wealth of CRE expertise and explore the latest trends and updates from the world of commercial real estate. In this episode, Crexi's Yannis Papadakis sits down with Ryan and Kishan to cover the current landscape of hospitality-to-multifamily conversions, where opportunities lie in waiting, how public and nonprofit entities are helping drive more affordable housing, and much more. Their wide-ranging conversation includes:Introductions and early steps along their CRE career pathsKey mentors and important lessons learned that set them up for future success.The importance of treating each client as a unique case, being able to pivot,  and how to create meaningful value in business relationshipsWhat makes hotels such well-positioned assets for conversions and adaptive reuseWhere investors are currently focusing from a market and growth perspective on adapting hotelsWhat goes into the conversion process and how to evaluate whether an asset fits the criteria for a good conversion projectComparing potential upsides and challenges when converting hotels to multifamily or other adaptive reuseIncentives for pursuing hotel conversions, including tax credits and other funding opportunitiesThe most important advice investors should consider when evaluating a hotel conversion.Rapid-fire questions and sign-offs.And much more!If you enjoyed this episode, please subscribe to our newsletter to receive the very next one delivered straight to your inbox. For show notes, past guests, and more CRE content, please check out Crexi Insights.Ready to find your next CRE property? Visit Crexi and immediately browse hundreds of thousands of available commercial properties.Follow Crexi:https://www.crexi.com/​ https://www.crexi.com/instagram​ https://www.crexi.com/facebook​ https://www.crexi.com/twitter​ https://www.crexi.com/linkedin​ https://www.youtube.com/crexiAbout Ryan Bodine:As SVP at NewGen, Ryan Bodine primarily focuses on representing and identifying hospitality investment opportunities nationwide for his domestic and international partners.Before NewGen, Ryan sourced foreign direct investment for Green Card Fund, an EB-5 Invest to Immigrate Regional Center, worked as an Executive Consultant for an education reform organization, and owned an international promotional product company.Ryan attended college at the University of Hawaii at Manoa, Roehampton University in London, and finished his degree in International Business from Arizona State University, graduating Summa Cum Laude.He is a member of the Asian American Hotel Owners Association, Arizona Lodging Tourism Association, Urban Land Institute, Arizona Association of Economic Development, the Greater Phoenix Economic Council, the Phoenix Committee on Foreign Relations, and the Global Shapers Phoenix HUB Community.About Kishan Gohel:Kishan is a W. P. Carey School of Business graduate at Arizona State University. He brings a wealth of business management knowledge from being around a hard-working family that owned various businesses while growing up.Kishan has spent much time in hotel brokerage curating new relationships and building existing client friendships. He has extensive experience in market research, which sets him apart when he secures a buyer for his listings and helps his clients find the next business opportunity. When the world endured the pandemic in 2020, travel demand fell, and the need for affordable housing increased. With government relief funds distributed through multiple channels, Kishan and his partners saw an opportunity to help clients sell their hotels as a conversion to an alternative use. He has successfully assisted non-profit organizations and investors to convert hotels to market-rate apartments, affordable/transitional housing, and behavioral health.In his spare time, he enjoys spending time with his family, going to car shows, and being outdoors in Arizona's beautiful 300+ days of sunshine.

We in the West appear to be at a year zero, with the seeming end of the relative peace and prosperity we took for granted. For years our politicians have said they were going for growth and would ensure that those with least would benefit disproportionately from the proceeds of that growth. They've failed. Growth has vanished. The poorest are desperately struggling to heat their homes and to eat. Confidence in our fundamental institutions has been undermined by leaders who have an uncomfortable relationship with the truth and by an economy that has mainly served the richest.In their new book Bust?, award-winning journalist, ITV political editor Robert Peston and co-author Kishan Koria ask: if the chaos of the last few years marks the end of the old order as we knew it, what will and should follow, to rebuild prosperity, and restore a sense of national pride and solidarity of purpose? The time for pessimism and fatalism is over, they argue – now we need urgently to look for answers.Join Robert and Kishan at the RSA to begin the debate about what could go right for our economy, politics and society – and how we might hope again.#RSAeconomyBecome an RSA Events sponsor: https://utm.guru/ueembDonate to The RSA: https://utm.guru/udNNBFollow RSA Events on Instagram: https://www.instagram.com/thersaorg/Follow the RSA on Twitter: https://twitter.com/theRSAorgLike RSA Events on Facebook: https://www.facebook.com/theRSAorg/Listen to RSA Events podcasts: https://bit.ly/35EyQYUJoin our Fellowship: https://www.thersa.org/fellowship/join

It's that time of year in the Northern Hemisphere, a time when chill autumn pushes us from the sidewalks into warm cafes for a thickly spiced latte and a hearty baked treat to ward us against the cold. Far to the South, spring arrives and the cackling trees and warming sun make a streetside coffee shop a delightful stop for an iced coffee and a delicate pastry as you pass the time. Is there anything so versatile, so timeless, and so persistent in our cities as coffee and the pleasantry of a soothing drink on a hard day? Yes, in fact.It's Death.In this Halloween special edition of Say it in Red, Sara and Runa are joined by returning guest and featured Melbourne Correspondent Bismuth who guides them, their Australian Psychopomp, through the laneways and backrooms of Necrobarista (2020). The game begins as a wayward and tired millennial, Kishan, wanders into a cafe and finds himself surrounded by a lively cast of people almost as odd as his present condition.  Kishan is dead, freshly so, and while coming to grips with his mortality and surroundings he also gets to know Maddy, the owner of The Terminal - a cafe that serves as the liminal space where spirits of the dead can linger for just 24 hours before passing on to whatever awaits them after the mortal world. Maddy is also a Necromancer and the cafe's current head barista, hence the title, and she spends much of her time wrangling drinks as Ashley, a teenager obsessed with robotics and caffeine and communism, fiddles with complex and paranormal machinery around the building. All the while Maddy's former boss and mentor, Chay, tries to keep everything in balance and everyone happy even as Kishan plummets into an existential crisis and paranormal debt collector, Ned Kelly (yes, the historical Ned Kelly) arrives to remind Maddy of what The Terminal owes. You see, people are only supposed to stay in the cafe for 24 hours before moving on, but Maddy and Chay aren't fond of kicking people out or keeping a stopwatch running for each and every customer. They've let far too many people stay far longer than a single day, and that Council of Death needs those hours back to preserve the balance. One way or another, the debt of time has to be paid even as those in the Terminal grapple with the weight of grief and loss seeping in around them.In addition to this discussion of Necrobarista, Bismuth prepares an Australian Slang quiz for Runa and Sara - let's stick around to see just how many times our hosts are fooled by fake terms, misdirections, and how often they manage to mangle the meaning of this Melbourne terminology. As always, if you enjoy our show please consider rating us and leaving a review wherever you listen to podcasts! Our patreon (at patreon.com/sayitinred) also hosts a growing number of bonus episodes, released around the second week of each month, so subscribe now to get access to even more Say it in Red to see you through the autumnal (or vernal) season.Content Warnings for this episode:In-depth discussions of death, mortality, and loss occur throughout this episode. 

On this episode of the show, we travel around the world to discuss England v Black Caps, Australia v South Africa and the first few Asia Cup games.The first three T20s between England and New Zealand weren't even moderately close, but there were still plenty of talking points:How aggressive will Finn Allen be at the World Cup? And how consistent does he need to be across the tournament for his overall performance to be treated as a success?Is Adam Milne in better form than Lockie Ferguson?Kane Williamson is going to the World Cup - what does that mean for Will Young, Mark Chapman, Jimmy Neesham and Rachin Ravindra?Is all the chopping and changing of players an issue for the Black Caps?How can England make room for Harry Brook in their squad?And what role will Gus Atkinson play?Australia have dominated their T20 series with South Africa, and we look at which of the Aussie fringe players are pushing hard for a World Cup role.Does Marcus Stoinis' success with the ball ease any concerns about Australia's 5th bowling option?Will Tanveer Sangha play a significant part in the World Cup?How much pressure is David Warner under?Are South Africa just tricking everyone?And have the major white-ball tournaments taken on extra significance for South Africa now that they appear to have relegated the Test game?The Asia Cup pool stages are underway - Pakistan's bowling attack is still very good, Ishan Kishan has surely locked down India's wicketkeeping spot and we debate whether Sri Lanka, Bangladesh and Afghanistan can provide more threat than banana skins during the upcoming World Cup.We round out the show with more New Zealand news - a new CEO, Corey Anderson's BBL gig and an impressive win against Australia A.We'll be back again next week, but in the meantime, please take the time to give us a like, follow, share or subscribe on all our channels (@toporderpod on Twitter & Facebook, and @thetoporderpodcast on Instagram & YouTube) and a (5-Star!) review at your favourite podcast provider, or tell a friend to download. It really helps others find the show and is the best thing you can do to support us. You can also find all our written content, including our Hall of Fame series, at our website.You can also dip back into our guest episodes - including chats with Shane Bond, Finn Allen, Jeetan Patel, Sophie Devine, Colin 'Funky' Miller, Matt Henry, Barry Richards, Frankie Mackay, George Dobell and many more fascinating people from all across the cricketing world. And if you'd like to reach out to us with feedback, questions or guest suggestions, get in touch at thetoporderpodcast@gmail.com.Thanks for listening.

On this week's episode we discuss the #indvpak match at #AsiaCup2023. India were 66-4 before Pandya and Kishan put together a partnership. Shaheen Shah Afridi took 4 wickets before rain ended the match.

After three matches in the Asia Cup with Pakistan through to the next round and Bangladesh in a must-win, Kaustubh Kumar, Vishal Dikshit and Karthik Iyer try to make sense of the early signs of the tournament.

Rising costs are having an impact on almost everyone, but that impact is very different for different social groups. Is anyone managing to make a difference to their own budget, however small? Whether they be high earners or low income households, how are people taking control of their finances? Felicity Hannah meets Peter who lives alone in a rented flat in Stoke and has a disability that prevents him from working; Hollie, a new mum, living with her fiancé in Wigan, who's trying to juggle money while on maternity leave with the rising costs of having a small baby. And Kishan, one of many people being bitten by monthly mortgage rate hikes. He lives in London and has three mortgages; his own plus two buy to lets. The programme also talks to Dr Gemma Tetlow Chief Economist at the Institute for Government to ask what does Peter, Hollie and Kishan's experience tell us about the cost of living crisis across the nation. Are households surviving or thriving? Series Producer Smita Patel Editor Clare Fordham Studio Engineer Rod Farquhar

What if you could unlock the hidden potentials of real estate syndication? Picture yourself delving deep into the intricacies of SEC 506B and 506C syndications, learning the criteria for becoming an accredited investor, and exploring vineyards, emergency clinics, private practice medical offices, and more as possible investment opportunities. This is the journey we embark on with real estate guru, Kishan Golla, who graces us with his wealth of experience from over 25 deals, and more than 4,000 doors in the commercial real estate market.As we navigate the world of real estate investment, we also confront its inherent challenges and risks. Kishan generously shares the realities of evolving interest rates, fluctuating insurance costs, labor and payroll changes due to the pandemic and their implications for your return on investment. We tackle the nitty-gritty, from the importance of investing in landlord-friendly communities to the potential returns an investor can expect and the average life cycle of a syndication.We conclude our insightful journey with Kishan by discussing diverse investment options and considerations: single-family homes, self-storage, and medical syndications. He reveals critical tax implications in retirement investments, and how to structure a deal to avoid UBIT and UDFI taxes associated with self-directed IRA investments. As we wrap up, one thing resonates: the paramount importance of honesty in syndication. Join us on this exploration and let Kishan's expertise guide you through the rewarding landscape of real estate syndication.RECN Facebook page  https://www.facebook.com/groups/5670625079733713Kishan Golla Email  kishan@vetexequity.comPhone (620)-704-1690

This week we take a break from our regularly scheduled programming because Nina always gets sick on weeks when she is supposed to be the one hosting, so Kishan is going solo like a bird from the nest for the first time. Will he fly or crash and burn as he gives you updates to stories that WCRH has covered throughout almost 3 years of podcasting

Episode 135: Exercise in Diabetes    Kishan and Princess explain how exercise lowers or raises blood glucose levels in diabetes. Dr. Arreaza adds some comments about insulin resistance.  Written by Kishan Ghadiya, MSIV, Ross University School of Medicine. Comments by Princess Enuka, MSIV, Ross University School of Medicine; and Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Today is April 7, 2023. Ep. 135.Intro:It is widely known exercise is paramount for all individuals. The American Heart Association recommends at least 150 minutes of moderate-intensity exercise weekly for general health. Exercise is particularly important in patients with diabetes, who require extensive lifestyle modification to manage their sugar levels. However, it is not well known how glucose metabolism changes when patients with diabetes exercise.My patient in the clinic.I recently saw in the clinic a young patient newly diagnosed with type 2 diabetes who asked about how his exercise was helping his sugar levels. He was confused because he heard that exercising allows for better glucose control but complained that his sugar levels were higher after exercising.To understand what is going on in this patient, it is important to understand the underlying pathophysiology of diabetes. First off, the two most common types of diabetes are type 1 and type 2. Type 1 occurs when the pancreas stops producing insulin altogether. Type 2 occurs when the insulin secreted by the pancreas is no longer effective in normalizing blood sugar levels; the body is not able to utilize glucose efficiently, the number of calories consumed exceeds the body's demands, and thus increasing body weight, which leads to insulin resistance and eventually pancreatic beta-cell exhaustion. Diabetes is thus a disease state of prolonged hyperglycemia and confers many long-term complications such as accelerated cardiovascular disease, neuropathy, nephropathy, and retinopathy.How does exercise lower blood glucose? Once patients are diagnosed with diabetes, management is lifelong, and it takes considerable mental and physical effort to manage this change in health. Exercise is a key metric in diabetic management because lowering blood sugar is as simple as using excess glucose to create energy in our muscles. There are two main mechanisms in how exercise has a positive effect on diabetes. The first mechanism is that exercise directly increases insulin sensitivity by enhancing the muscles' ability to effectively respond to insulin, thus allowing for better use of insulin on board (IOB). This benefit is not only seen during exercise itself but also up to 24 hours after exercise is complete. This means many patients with controlled diabetes can see a euglycemic effect up to 1 day after exercise.The second mechanism is that increased glucose uptake into muscle does not require insulin secretion. In other words, active muscle use during exercise allows for glucose uptake even without the use of any insulin and is very effective in lowering blood sugar levels. Muscles have a higher metabolic rate than fat tissue. It means that even without exercising, a person with a higher muscle mass has a higher basal metabolic rate.What type of exercise would be the most effective in controlling blood sugar? The data is very clear that there is no relationship between exercise technique and glucose level, but there is a relationship between exercise intensity and glucose levels. In other words, patients wanting better blood sugar outcomes may choose whatever exercise regimen as long as they are able to do high-intensity exercise (i.e., resistance training, strength training, High-intensity interval training, HIIT).Anaerobic vs. aerobicBlood sugar levels during exercise will be different based on the types of exercise patients choose. For example, high-intensity anaerobic exercise (such as weightlifting) causes large spikes of blood sugar because the liver creates large amounts of glucose for anaerobic glycolysis. On the other hand, high-intensity aerobic exercise (such as running) confers lower blood glucose. Keep in mind both types of exercise confer excellent long-term patient outcomes, but the disparity in blood sugar is important to note as it can lead to confusion in patients that are very actively monitoring their sugar levels.Hyperglycemia after anaerobic exercise.So, returning to my patient mentioned above, further history revealed that he does weightlifting two or three times a week. Hyperglycemia would therefore be expected during and immediately after anaerobic exercise due to large amounts of glycolysis requiring the liver to create sugar. This patient's increased blood sugar seen after exercising would not be a cause for concern as this is part of normal human body physiology.___________________________________Conclusion:  Now we conclude episode number 135, “Exercise in Diabetes.” Kishan explained that exercise improves insulin sensitivity and promotes muscle growth for improved glucose metabolism. Princess explained that anaerobic exercise may cause a transient rise in glucose while aerobic exercise causes glucose control over a longer period. Dr. Arreaza explained that insulin sensitivity is lost when we give frequent “high shots of sugar” to our body.This week we thank Hector Arreaza, Kishan Ghadiya, and Princess Enuka. Audio editing by Adrianne Silva.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Kirwan JP, Sacks J, Nieuwoudt S. The essential role of exercise in the management of type 2 diabetes. Cleve Clin J Med. 2017 Jul;84(7 Suppl 1):S15-S21. doi: 10.3949/ccjm.84.s1.03. PMID: 28708479; PMCID: PMC5846677. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846677/Riddell M, Perkins BA. Exercise and glucose metabolism in persons with diabetes mellitus: perspectives on the role for continuous glucose monitoring. J Diabetes Sci Technol. 2009 Jul 1;3(4):914-23. doi: 10.1177/193229680900300439. PMID: 20144341; PMCID: PMC2769951. https://pubmed.ncbi.nlm.nih.gov/20144341/Zahalka SJ, Abushamat LA, Scalzo RL, et al. The Role of Exercise in Diabetes. [Updated 2023 Jan 6]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from  https://www.ncbi.nlm.nih.gov/books/NBK549946/Royalty-free music used for this episode: “Gushito - Burn Flow." Downloaded on October 13, 2022, from https://www.videvo.net/

Heyo, in this weeks episode we have a special guest Kishan, we talk about his life, becoming an adult in the system, being a man and being a parent. For our check in we talk about the Restrict act, Brendan talks about his motives and Kishantalks about learning discipline. When we come up Brendan talks about his struggle with weed, Kishan talks about parenting and speeches, while Jaxon talks about chefin it up. Intro Song https://www.youtube.com/watch?v=sXElQ-TQ4mg

Dr Kishan discusses the use of MRI-guided SBRT in prostate cancer to reduce acute genitourinary and gastrointestinal toxicity; findings from the MIRAGE study; and how MRI-guided SBRT allows for tighter planning margins, thereby reducing both physician-reported and patient-reported bowel and bladder toxicities.

Joel and Kishan go for a walk in East Coast Park, a hostage situation in which Joel rants at Kishan on a variety of subjects, with some breaks.

This week, Ashwin is joined by DJ and we talk about King Kohli's supreme form as India defeat Sri Lanka 3-0 in the ODIs. We also cover selection quandaries - Gill over Kishan, Kuldeep back in the side, KL Rahul's role, Siraj in ODIs, SKY in Tests, Shaw in T20s and much more! - You can follow Edges & Sledges on social media: Twitter: https://twitter.com/1tip1hand Discord: https://discord.gg/D7UrjwyyZ6 Instagram: https://www.instagram.com/1tip1hand Facebook: https://www.facebook.com/1tip1hand - You can download the 99.94DM app right here: iOS: https://apple.co/3ovg0M5 Android: https://bit.ly/3S29f1R You can also join the 99.94DM Community on our socials right here: Twitter: https://twitter.com/9994DM Instagram: https://www.instagram.com/99.94dm/ LinkedIn: https://www.linkedin.com/company/9994dm/ And our Podcasts are right here: Spotify: https://spoti.fi/3S643KC Apple Podcasts: https://apple.co/3otgVwz

This week we discuss India's men losing to Bangladesh 2-1 in the #BanvInd ODI series, but a bonus match for Ishan Kishan where he made a tremendous double century. We also preview the #banvsind test series and talk about the India Women's stunning win over Australia in a Super Over and some of the test match action from across the globe. #auswvsindw #pakveng. - You can follow Edges & Sledges on social media: Twitter: https://twitter.com/1tip1hand Discord: https://discord.gg/D7UrjwyyZ6 Instagram: https://www.instagram.com/1tip1hand Facebook: https://www.facebook.com/1tip1hand - You can download the 99.94DM app right here: iOS: https://apple.co/3ovg0M5 Android: https://bit.ly/3S29f1R You can also join the 99.94DM Community on our socials right here: Twitter: https://twitter.com/9994DM Instagram: https://www.instagram.com/99.94dm/ LinkedIn: https://www.linkedin.com/company/9994dm/ And our Podcasts are right here: Spotify: https://spoti.fi/3S643KC Apple Podcasts: https://apple.co/3otgVwz

This week we cover the #IndvSA T20s and #IndvsSA ODI series. We also talk about the women's #AsiaCup and Bumrah's injury. Check out the Edges & Sledges Cricket Podcast community on Discord:- https://discord.gg/D7UrjwyyZ6You can follow Edges & Sledges on Twitter, Instagram, and Facebook: @1tip1handYou can listen to this show and other incredible shows on the new and improved IVM Podcast App on Android: https://ivm.today/android or iOS: https://ivm.today/ios

“The industry as a whole needs to do a better job of coming together. This competing messaging is not helping anyone." -Kishan Vasani In this era of technological innovation, one of the most promising solutions for improving our food experience is artificial intelligence (AI). AI is a technology that allows computers to learn from data and make decisions based on that information. It can be used for a variety of purposes, including personalization of services. For instance, AI is used to identify food trends and predict customer preferences based on moods or other factors such as age or gender which allows restaurants to customize their meals based on changes in customer behavior over time. Co-founded by Kishan Vasani, Spoonshot aims to determine the future of food through their AI called #foodbrain. They utilize over 28k data resources that include research, articles, social conversations, menus, and more to understand consumer insights, marketing, and product development. This platform aims to help companies and restaurants make better decisions and produce desirable outcomes. Their clients include big companies such as Nestle, Unilever, Mars, Dan One, and Suntory.   Listen in as Justine and Kishan help us better understand the nuances and everything that goes into food personalization, the factors that affect our preferences, how we can be more transparent in the food space conversation, and how companies can work together rather than destroy each other through unnecessary competition.     Meet Kishan: Kishan Vasani is the co-founder of Spoonshot, a tech startup that leverages food science and AI to predict food trends for CPG and FMCG companies. He is also the co-founder and chairman of One Cause, an organization investing in education solutions for poverty. He studied management at Ashton University in Birmingham. Kishan loves tech, food, and startups. He is a big sports fan and plays about any sport but football is his number one. Website Twitter LinkedIn YouTube Medium Connect with NextGen Purpose: Website Facebook Instagram  YouTube Linkedin Episode Highlights: 01:18 Personalizing Food 06:28 Understanding the Local View of Food 12:38 Occasions Breed Innovation 17:40 Food and the Age of Information 21:57 Get Ready for Future Food-Tech London!